Our Pricing

Understanding Wegovy BMI Requirements in the UK

Published on: June 03, 2026

Understanding wegovy bmi requirements uk criteria is essential before starting treatment. At Cured Pharmacy, our UK-registered prescribers assess eligibility based on MHRA-approved guidelines, typically requiring a BMI of 30 or above, or 27 or above with at least one weight-related health condition. Wegovy (semaglutide) is available from £79.00 following a free online consultation that takes under three minutes.

What Are the Wegovy BMI Requirements UK Prescribers Follow?

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. These thresholds align with NICE guidance on pharmacological weight management and reflect the eligibility criteria used in the pivotal STEP clinical trial programme.

Your BMI is calculated by dividing your weight in kilograms by your height in metres squared. A BMI of 30 or above is classified as obese, whilst 27–29.9 is considered overweight. If you fall into the overweight category, you may still qualify for Wegovy if you have a diagnosed weight-related condition that increases your cardiovascular or metabolic risk [1]. Our UK prescribers will review your full medical history during your free consultation to determine whether Wegovy is clinically appropriate for you.

It's important to note that Wegovy is not suitable for everyone. Contraindications include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or previous serious hypersensitivity to semaglutide [2]. Pregnant or breastfeeding women should not use Wegovy, and treatment should be stopped at least two months before a planned pregnancy.

How Wegovy Works: The Science Behind Semaglutide

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone involved in appetite regulation and glucose metabolism [2]. By activating GLP-1 receptors in the brain, semaglutide reduces hunger, increases feelings of fullness, and helps you consume fewer calories without the constant struggle against appetite.

In the landmark STEP 1 trial, participants receiving once-weekly semaglutide 2.4 mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [3]. Importantly, 86.4% of participants on semaglutide lost at least 5% of their body weight, and more than half lost 15% or more — outcomes that significantly exceed those seen with older weight-loss medications.

Semaglutide also slows gastric emptying, which prolongs the sensation of satiety after meals, and improves glycaemic control in patients with type 2 diabetes [2]. These combined effects make Wegovy a powerful tool for sustainable weight management when used alongside a reduced-calorie diet and increased physical activity.

Wegovy Dosing Schedule and Titration

Wegovy is administered as a once-weekly subcutaneous injection, starting at a low dose of 0.25 mg for the first four weeks. The dose is gradually increased every four weeks — to 0.5 mg, 1 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg — to minimise gastrointestinal side effects such as nausea and vomiting [1]. This titration schedule is critical for tolerability and should not be accelerated without guidance from your prescriber.

Wegovy Eligibility Criteria Beyond BMI

Whilst BMI is the primary eligibility criterion, UK prescribers also consider your overall health profile, current medications, and weight-loss history. If you've tried other weight-management strategies — such as calorie restriction, increased physical activity, or behavioural therapy — without sustained success, Wegovy may be an appropriate next step, subject to prescriber approval.

Certain medical conditions may affect your suitability for Wegovy. If you have a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy complications, your prescriber will carefully weigh the risks and benefits [2]. Similarly, if you're taking other medications that affect blood sugar or appetite, dose adjustments or alternative treatments may be necessary.

Age is another factor: Wegovy is licensed for adults aged 18 and over. It is not currently approved for use in children or adolescents under 18 in the UK, although paediatric trials are ongoing. Our clinical team at Cured Pharmacy will ensure that Wegovy is both safe and appropriate for your individual circumstances before issuing a prescription.

Weight-Related Comorbidities That May Qualify You

If your BMI is between 27 and 29.9 kg/m², you may still be eligible for Wegovy if you have at least one of the following conditions: type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease [1]. These comorbidities significantly increase the health risks associated with excess weight, and weight loss can lead to meaningful improvements in disease control and quality of life.

Starting Wegovy at Cured Pharmacy: What to Expect

At Cured Pharmacy, we've made accessing Wegovy straightforward and transparent. You'll begin with a free online consultation that takes less than three minutes to complete. Our UK-registered prescribers will review your medical history, current medications, weight-loss goals, and any relevant comorbidities to determine whether Wegovy is clinically appropriate for you.

If approved, your prescription is processed immediately, and your Wegovy pen is dispensed from our UK-registered pharmacy and delivered in 100% discreet packaging. We provide clear instructions on injection technique, storage, and what to expect during the titration phase. Our clinical team is available by phone on (+44) 116 4646009 if you have any questions or concerns during your treatment.

We believe in transparent pricing: Wegovy starts from £79.00 at Cured Pharmacy, with the exact cost depending on your prescribed dose. Unlike some providers, we show you the price before you complete your consultation, so there are no surprises. All our medicines are genuine, UK-licensed products sourced from reputable manufacturers.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Wegovy are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal pain [2]. These symptoms are usually mild to moderate and tend to improve as your body adjusts to the medication, particularly if the dose is increased gradually according to the recommended schedule.

To minimise nausea, eat smaller, more frequent meals, avoid high-fat or spicy foods, and stay well hydrated. If you experience persistent vomiting or signs of dehydration, contact your prescriber promptly. In rare cases, dose reduction or temporary treatment interruption may be necessary.

Serious but uncommon side effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking other glucose-lowering medications) [2]. If you develop severe abdominal pain that doesn't go away, yellowing of the skin or eyes, or symptoms of low blood sugar such as dizziness, sweating, or confusion, seek medical attention immediately. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), and the clinical team at Cured Pharmacy are here to support you throughout your treatment journey.

When to Contact Your Prescriber

Always contact your prescriber if you experience persistent or severe side effects, if you're unable to tolerate the current dose, or if you have any concerns about your treatment. Never adjust your dose or stop Wegovy without professional guidance, as abrupt discontinuation may lead to rapid weight regain.

Wegovy vs Other Weight-Loss Treatments: Making an Informed Choice

Wegovy is one of several prescription weight-loss treatments available in the UK, each with distinct mechanisms, dosing schedules, and clinical profiles. Understanding these differences can help you and your prescriber choose the most suitable option for your needs.

Saxenda (liraglutide) is another GLP-1 receptor agonist, but it requires daily injections rather than once-weekly dosing. Clinical trials suggest that semaglutide (Wegovy) produces greater average weight loss than liraglutide [3][4]. Mounjaro (tirzepatide) is a newer dual GIP/GLP-1 receptor agonist that has shown even higher efficacy in some trials, though it is not yet as widely available or as competitively priced as Wegovy.

Oral medications such as Orlistat and Mysimba work through different pathways — Orlistat reduces fat absorption in the gut, whilst Mysimba combines naltrexone and bupropion to reduce appetite and cravings. These may be appropriate if you prefer not to use injectable treatments, though average weight loss tends to be more modest compared to GLP-1 therapies [4]. Your UK prescriber will discuss all suitable options during your consultation.

Scientific References

1. European Medicines Agency. (2021). Wegovy (semaglutide): Summary of Product Characteristics. EMA. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Davies, M., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.